Area of research
Cancer Research · Pathology and Forensic Medicine
Research interest
Research interests include Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, Breast Implant and Reconstruction, and BRCA gene mutations in cancer.
Obesity-associated changes in molecular biology of primary breast cancer
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials
Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants
First results of the preoperative accelerated partial breast irradiation (PAPBI) trial
Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial
Long-term impact of the 70-gene signature on breast cancer outcome
Mammographic screening detects low-risk tumor biology breast cancers
Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis
Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
Investigation of gene‐environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors
Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013